Work

THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial

Year: 2013

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2013-eular.730

Authors: J.S. Smolen, J. Kay, R. Landewé, E.L. Matteson, N. Gaylis, J. Wollenhaupt, F.T. Murphy, C. Han, T. Gathany, S. Xu, Y. Zhou, E.C. Hsia, M.K. Doyle

Institutions: Klinik Hietzing, Medical University of Vienna, UMass Memorial Medical Center, Atrium Medisch Centrum Parkstad, University of Amsterdam, Mayo Clinic, Arthritis and Rheumatic Disease Specialties, Schön Klinik Hamburg Eilbek, Altoona Center for Clinical Research, Janssen Research & Development (United States)

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2321695235

Cites:

Cited by: 4

Related to: 10